StressGen completes Phase II enrollment

StressGen (TSE:SSB) completed enrollment of a 52-patient, double-blind, placebo-controlled U.S. Phase II study of its HspE7 to treat genital warts caused by human papillomavirus (HPV) (see BioCentury...